Introduction

As the principle cause of coronary artery disease (CAD) and myocardial infarction (MI), atherosclerosis is a leading cause of mortality and morbidity worldwide. Atherosclerosis describes a chronic, systemic inflammatory process, in which plaques develop in arteries and limit blood flow. Thrombotic occlusion of atherosclerotic vessels most commonly occurs as a consequence of plaque rupture or erosion. Studies with intracoronary imaging techniques have revealed that plaques that are vulnerable to rupture have hallmark features, including high plaque volume, necrotic core, lipid and inflammatory cell content, thin fibrous caps, intraplaque neovascularization and hemorrhage (1). Multiple unstable plaques often co-exist in the coronary vasculature. Although large clinical trials have demonstrated the benefits of primary and secondary prevention therapies targeted against CAD risk factors, such as dyslipidemia (2) and blood pressure (BP) (3), the prevalence of plaque rupture or erosion leading to initial or recurrent MI remains high (4).

In order to optimize management of atherosclerosis and its complications, there is a continued need to better understand the natural history of this disease, and its responsiveness to different treatments. This has been
made increasingly possible by advances in various coronary imaging techniques that allow the serial assessment of plaque burden and composition over time. These modalities include invasive intravascular ultrasound (IVUS), optical coherence tomography (OCT) and near infrared spectroscopy (NIRS), and less invasive coronary computed tomography angiography (CTA), magnetic resonance imaging (MRI) and molecular imaging with positron emission tomography (PET). Unlike conventional coronary angiography (CAG), which informs about the degree of luminal stenosis caused by plaque, these other techniques also provide assessment of the vessel wall itself and its atherosclerotic substrate. Their ability to measure and characterize baseline plaque burden and the rate of progression in serial observations over time provides a means of predicting risk for adverse cardiovascular outcomes, namely coronary revascularization, MI and death (5). These coronary imaging modalities therefore play an integral role in preclinical and clinical studies designed to evaluate the natural history of CAD and its responsiveness to traditional and experimental therapeutic interventions. In this review, we discuss the lessons learned from these imaging studies and how they continue to shape our understanding of anti-atherosclerotic therapies.

**Invasive modalities for serial CAD assessment**

**Coronary angiography**

CAG has traditionally been used to identify stenotic lesions within the coronary arteries. Randomized trials using serial CAG have shown the effects of medical therapies on coronary disease (6). However, there are limitations to using this imaging technique to quantify atherosclerotic plaque burden. Quantitative coronary angiographic measurements are associated with a lack precision due to variations in equipment and inter-observer differences (7). The imaging produced by CAG is a two-dimensional silhouette of the lumen, and does not include the vessel wall. The reduction in the size of the lumen does not occur until the disease has reached an advanced stage. This limitation has led to a need for vessel wall-based imaging modalities.

**Intravascular ultrasound (IVUS)**

IVUS allows the placement of a catheter containing a high-frequency ultrasound transducer within the lumen of coronary arteries. Early use of IVUS focused on the role of assisting in the deployment of stents to improve procedural and longer-term clinical outcomes (8). The ability to place an ultrasound transducer in close proximity to the vessel wall enables cross-sectional imaging (Figure 1A). Therefore IVUS provides a more extensive view than CAG of the distribution and nature of plaque burden within the vessel wall (10). Early autopsy studies confirmed that coronary artery segments with a normal angiographic appearance invariably harbor plaque visible on IVUS (11). The ability to visualize and perform serial measurements of the lumen and surrounding vessel wall in multiple contiguous cross-sections enables reproducible quantification of plaque burden, and IVUS represents the current gold standard for this purpose. As described below, numerous studies have used serial IVUS imaging to evaluate the impact of medical therapies, such as statins for cholesterol lowering, upon progression or regression of coronary atherosclerosis.

**Optical coherence tomography (OCT)**

OCT is another intravascular imaging modality that uses near-infrared light, usually of a wavelength of approximately 1,300 nm, to create images of plaque atheroma in the coronary arteries (Figure 1B). Its greatest advantages over other imaging modalities is its high spatial resolution (approximately ten-times higher than that of IVUS) with an axial resolution of up to 10 μm and a lateral resolution of up to 20 μm (12,13). This increase in resolution provides high-quality imaging and quantitative analysis of various components of atheroma below the intimal endothelial surface, including fibrous cap, vascular microchannels, microcalcification, lipid content and macrophage burden (14,15). Imaging of these features gives OCT a potential role in assessing factors that increase the vulnerability of atherosclerotic plaques. However, the benefits of high imaging resolution are somewhat offset by OCT’s poor tissue penetration, making it difficult to image the full thickness and deeper layers of atherosclerotic plaques, especially in large vessels, while interference from blood can also adversely affect image quality.

**Virtual histology (VH)**

There is now increasing interest to look beyond the effect of medical therapies on plaque burden, and also investigate how they modify the composition of plaque. Studies have demonstrated that lesions containing more lipid, inflammation and necrotic material are more
vulnerable (16), with greater propensity to plaque rupture and ischemic events (1). Although conventional ultrasonography is able to detect calcium and characterize the degree of echogenicity of plaque, it lacks the resolution to comprehensively monitor therapeutic-induced changes in plaque composition.

Virtual histology IVUS (VH-IVUS) is a technique based on advanced radiofrequency analysis of reflected ultrasound signals. A reconstructed color-coded tissue map of plaque composition is superimposed onto cross-sectional images of the coronary artery obtained by grayscale IVUS, that distinguishes between fibrous, fibrofatty, necrotic core and dense calcific material (17). VH-IVUS has been applied in clinical settings to demonstrate the association between cardiovascular events and plaque containing greater quantities of both necrotic and lipidic material (18). These associations have led to the integration of VH-IVUS in studies evaluating the biological effects of anti-atherosclerotic therapies.

Near-infrared spectroscopy (NIRS)

NIRS is based on the absorbance of light by organic molecules, and determines characteristics of the chemical composition of tissue [Figure 1](#) (8). It has been applied in the detection of atherosclerotic plaque and the evaluation of its composition. NIRS has the advantage of being non-invasive, allowing for repeated imaging without additional exposure to radiation. It provides valuable information about the lipid content of the plaque, distinguishing between different types of lipids and their distribution within the plaque [Figure 1](#) (8). This information is crucial for understanding the biological properties of the plaque and predicting its vulnerability to rupture.

Figure 1 (A) Example of a cross-sectional view of intravascular ultrasound imaging highlighting plaque burden; (B) example of coronary artery imaging with optical coherence tomography demonstrating atherosclerotic plaque; (C) example of atherosclerotic plaque imaging with a cross-sectional view of intravascular ultrasound highlighting plaque and near-infrared spectroscopy demonstrating lipid (yellow) content; (D, yellow dotted circle) example of noncontrast T1-weighted imaging of a plaque in the proximal segment of the LAD artery with a PMR of 1.08; (E, a-c) cross-sectional coronary CTA images of lesion. [Images A-C are original images, and images D, E, and a-c are adapted from (9)]. LAD, left anterior descending; CTA, computed tomography angiography.
components of tissue samples. Advances in catheter techniques have enabled NIRS imaging within coronary arteries (Figure 1C) (19). Early development of this imaging technique has been used to assess lipid and protein content within atherosclerotic plaque (20). While the NIRS signal has the capability to detect the spectra of the different molecules within plaque, at this stage it has primarily been applied to detect lipid. Spectroscopic information obtained from raw spectra is transformed into a probability of lipid core that is mapped to a red-to-yellow color scale, with low probability of lipid shown as red and high probability of lipid shown as yellow. Yellow pixels within the analyzed segment are then divided by all viable pixels to generate the lipid-core burden index (LCBI). Further work is required to broaden the application of NIRS to provide more comprehensive assessment of plaque, so that it can be used in serial studies to quantify plaque response to therapies.

Less invasive modalities for serial CAD assessment

Non-contrast computed tomography

The accumulation of calcium generally occurs relatively late in the atherosclerotic process. Non-contrast CT allows detection of calcium as a surrogate means of assessing coronary atheroma burden. Quantification of coronary artery calcium (CAC), most commonly using the Agatston score, has been well demonstrated to correlate with coronary atheroma burden on histology (21), and predict risk of cardiovascular events in asymptomatic patients (22,23). Although the utility of non-contrast CT calcium scoring has been studied extensively for risk stratification, it has limited ability to measure treatment effect and cannot be recommended for the evaluation of plaque progression in treated individuals.

Coronary computed tomography angiography (CTA)

Multidetector row CT (MDCT) has evolved rapidly resulting in improvements in spatial and temporal resolution with current scanners and prospective gating techniques, radiation exposure has been reduced to 2–5 mSv. Administration of iodinated contrast is required with associated risk of contrast-induced nephropathy. While the resolution of coronary CTA itself remains inferior to invasive atherosclerotic imaging techniques, it is still able to detect luminal stenosis of ≥50% anatomic severity with sensitivity approaching 100%, and specificity in the order of 85%, compared to CAG on a per patient basis (24,25). In contrast, it performs less well when compared against intracoronary pressure assessment, with 80% sensitivity and 67% specificity for detecting fractional flow reserve measurements of <0.80 (25). Owing to its ability to characterize plaque composition (calcified versus non-calcified) and arterial remodeling, coronary CTA may also identify patients at high risk of future cardiovascular events (26). In particular the presence of positive remodeling, low attenuation plaque (<30 Hounsfield units), spotty calcification, and the napkin ring sign each confer a high positive predictive value for future acute coronary syndrome (ACS) episodes, while their absence has a high negative predictive value (27).

In addition to its noninvasiveness, coronary CTA carries the distinct advantage of being able to qualitatively and quantitatively assess overall plaque burden in the entire coronary vasculature, with recent data showing that widespread, multivessel, nonobstructive CAD confers similar risk of event rates to localized obstructive disease (28). Various semi-quantitative methods have been used to score the degree of plaque in coronary segments using coronary CTA (24), with the best results shown for semiautomatic expert-guided measurements, as determined by comparison against IVUS (29). Although coronary CTA provides excellent correlation of individual plaque measurements with IVUS (29), it is limited in detecting small noncalcified plaques (<1 mm) and may misclassify plaque subcomponents (30). This is especially the case at the low radiation doses (≤1 mSv) which have become achievable with contemporary coronary CTA technology, and which otherwise would enable patients to more safely undergo repeat CCTA examinations.

Although consensus statements recommend that coronary CTA is “adequate” for excluding significant CAD in patients with chest pain symptoms and intermediate pretest probability of CAD, its use is not approved in asymptomatic individuals. Similarly, although implemented in the experimental setting to monitor plaque change over time, further data are required to validate the accuracy and reproducibility of serial coronary CTA before it can be used routinely for follow-up imaging of plaque.

Magnetic resonance imaging (MRI)

MRI is a noninvasive technique that offers the opportunity
to visualize vessel anatomy and differentiate atherosclerotic tissue without exposure to radiation, using features such as chemical composition, water content, molecular motion or diffusion. The recent improvements in MRI techniques such as T1-, T2- and proton-density-weighted imaging have provided the ability to produce information not only about plaque volume, but also composition in multiple arterial territories, including the aorta, carotids and main peripheral arteries, as demonstrated in animal models and human subjects (31-33). However, the resolution of 1.5-T Tesla MRI with or without contrast is lower than coronary CTA (1.0–1.5 vs. 0.5–1.0 mm), limiting the accurate visualization of coronary arteries. Other limitations of coronary MR angiography include its relatively long acquisition times and operator dependency, although these are being addressed by ongoing refinements.

In one multicenter study the sensitivity of non-contrast-enhanced whole-heart coronary MR angiography was 88% on a patient-based analysis for detecting ≥50% stenosis shown by invasive CAG, although specificity was only 72% (34). High-field-strength 3.0-T systems improve the signal-to-noise ratio of coronary MR angiography, such that diagnostic accuracy of 3.0-T contrast-enhanced imaging approaches that of some coronary CTA systems (35). However administration of contrast is not without risks, such as the potential for nephrogenic systemic fibrosis in patients with severe renal dysfunction who receive gadolinium agents, resulting in a recent FDA advisory. Repeat gadolinium-enhanced MRI studies have also been linked to the presence of deposits in the dentate nucleus and globus pallidus regions of the brain, which are as yet of uncertain significance.

Noncontrast T1-weighted imaging (T1WI) has been used recently to detect high-intensity coronary plaques (HIPs), which are thought to represent the presence of intraplaque lipid, with or without hemorrhage (36). Studies have now validated measurement of the plaque-to-myocardium signal-intensity ratio (PMR) of HIPs has been recently validated as a method for predicting acute coronary events (37), and for monitoring the response of atheroma to cholesterol-lowering therapy (Figure 1D,E) (9).

The status of coronary MR angiography is that its use is considered “inappropriate” for the routine, non-invasive assessment of CAD, except to assess for anomalous coronary arteries and coronary artery aneurysms in patients with Kawasaki disease (38). By extension, in the absence of more substantial data it can also not be recommended for the surveillance of coronary atherosclerosis in current clinical practice.

**Positron emission tomography (PET)**

Nuclear imaging techniques, such as PET, have the ability to target distinct mediators and regulators involved in the evolution of atherosclerosis. Several radionuclide-labeled tracers have been developed to image inflammation, angiogenesis, apoptosis and lipid metabolism (39). PET imaging with 18F-fluorodeoxyglucose (FDG) has been considered to be especially promising imaging modality for the identification of vulnerable lesions. However, coronary artery imaging remains difficult due to background FDG uptake by the myocardium, along with the low spatial resolution of PET and small size of coronary arteries, and artefactual noise from cardiac motion, making FDG-PET inadequate for clinical assessment of CAD. Furthermore, there is also the matter of total body radiation exposure which is in the order of 7 mSv with contemporary myocardial 18F-FDG PET imaging.

Experimental studies have demonstrated greater FDG uptake in plaques containing a large proportion of macrophages, suggesting that this approach may be used to evaluate the impact of therapies on the inflammatory composition of atherosclerotic plaques (40). More recently PET-based imaging of 18F-sodium fluoride uptake has been used to detect high risk features of unstable plaque in patients with carotid and coronary atherosclerosis (41). Although far from primetime, the integration of less invasive imaging techniques, such as MRI and PET with molecular targeted agents holds potential for evaluating new therapies on specific targets in atherosclerotic plaque that are associated with rupture (42).

**Treatment targets to modulate plaque progression**

The above imaging techniques have been used to assess modulation of coronary atherosclerosis in response to different established and novel medical therapies. As described below, the greatest body of work has been performed with serial IVUS imaging following cholesterol-lowering treatment with HMG-CoA reductase inhibitors (“statins”).

**Lowering low-density lipoprotein (LDL) (Table 1)**

The correlation between lowering levels of LDL cholesterol...
<table>
<thead>
<tr>
<th>Study and author</th>
<th>Disease cohort and study size</th>
<th>Intervention</th>
<th>Study design</th>
<th>Modality</th>
<th>Follow-up</th>
<th>Findings</th>
</tr>
</thead>
</table>
| FATS, Brown et al. (43) | High CV risk n=146 | Gp1 lovastatin 20 mg 2×/day + colestipol 10 g 3×/day  
Gp2 niacin 1 g 4×/day + colestipol 10 g 3×/day  
Gp3 conventional therapy + placebo | RCT | CAG | 30 months | Mean LDL-C change  
Gp1 −46% (P<0.001), Gp2 −32% (P<0.001),  
Gp3 −7% (P<0.05)  
Definite lesion progression  
Gp1 21%, Gp2 25%, Gp3 46%, P<0.005 |
| MARS, Blankenhorn et al. (44) | Stable CAD n=270 | Gp1 lovastatin 80 mg/day  
Gp2 placebo | RCT | CAG | 24 months | Total cholesterol change  
Gp1 −32%, Gp2 −1.8%, P<0.001  
LDL-C change  
Gp1 −38%, Gp2 −0.9%, P<0.001  
Mean stenosis change  
Gp1 +1.6%, Gp2 +2.2%, P>0.2 |
| REVERSAL, Nissen et al. (45) | Stable CAD n=654 | Gp1 pravastatin 40 mg/day  
Gp2 atorvastatin 80 mg/day | RCT | IVUS | 18 months | Mean LDL-C change  
Gp1 −25%, Gp2 −46.3%  
Mean PAV change  
Gp1 +2.7%, Gp2 −0.4%, P=0.02 |
| ASTEROID, Nissen et al. (46) | Stable CAD n=507 | Rosuvastatin 40 mg/day | Prospective, open-label blinded endpoints trial | IVUS | 24 months | Mean LDL-C change  
53.2%, P< 0.001  
Mean HDL-C change  
14.7%, P< 0.001  
PAV change  
0.98%, P<0.001 |
| SATURN, Nicholls et al. (47) | Stable CAD n=1,578 | Gp1 rosvastatin 40 mg/day  
Gp2 atorvastatin 80 mg/day | RCT | IVUS | 24 months | Final LDL-C  
Gp1 62.6±1.0 mg/dL  
Gp2 70.2±1.0 mg/dL, P<0.001  
Final HDL-C  
Gp1 50.4±0.5 mg/dL  
Gp2 48.6±0.5 mg/dL, P=0.001  
Median PAV change  
Gp1 −1.22%, Gp2 −0.99%, P=0.17 |

Table 1 (continued)
<table>
<thead>
<tr>
<th>Study and author</th>
<th>Disease cohort and study size</th>
<th>Intervention</th>
<th>Study design</th>
<th>Modality</th>
<th>Follow-up</th>
<th>Findings</th>
</tr>
</thead>
</table>
| EASY-FIT, Komukai et al. (48) | Unstable angina and untreated dyslipidemia n=70 | Gp1 atorvastatin 20 mg/day | Prospective, open-label blinded end-points trial | OCT | 12 months | Final LDL-C
Gp1 69 mg/dL, Gp2 78 mg/dL, P=0.039
Fibrous cap thickness increase
Gp1 69%, Gp2 17%, P<0.001 |
| YELLOW, Kini et al. (49) | Multivessel CAD n=87 | Gp1 rosuvastatin 40 mg/day | RCT | NIRS | 7 weeks | Median change LCBI4 mm max
Gp1 −149.1 (−210.9 to −42.9)
Gp2 +2.4 (−36.1 to 44.7), P=0.01 |
| SFHS, Arad et al. (50) | Asymptomatic, CAC score ≥80th percentile n=1,005 | Gp1 atorvastatin 20 mg/day + vitamin C 1 g/day + vitamin E (alpha-tocopherol) 1,000 U/day + aspirin 81 mg/day Gp2 placebo + aspirin 81 mg/day | RCT | CAC | Mean 4.3 years | Mean calcium score increase
Gp1 331±421 U, Gp2 323±385 U, P=0.80
ASCVD events
Gp1 6.9%, Gp2 9.9%, P=0.08 |
| EBEAT, Schmermund et al. (51) | Moderate calcified coronary atherosclerosis n=471 | Gp1 atorvastatin 80 mg/day | RCT | CAC | 12 months | LDL-C change
Gp1 106±22 to 87±33 mg/dL, P<0.001
Gp2 108±23 to 109±28 mg/dL
CAC score mean progression
Gp1 27%, Gp2 25%, P=0.65 |
| AQUAMARINE pilot study, Noguchi et al. (9) | Stable CAD n=48 | Gp1 pitavastatin 4 mg/day Gp2 placebo | Open-label, propensity score-matched study | MRI and CTCA | 12 months | LDL-C change
Gp1 125 to 70 mg/dL, P<0.001
Gp2 1.26 to 1.21 mg/dL, P=0.789
Change in PMR
Gp1 1.38 to 1.11, P<0.001
Gp2 1.22 to 1.49, P<0.001 |
| Tahara et al. (52) | n=43 | Gp1 simvastatin 5 or 10 mg/day Gp2 dietary management | RCT | 18FDG-PET | 3 months | LDL-C change
Gp1 30% reduction, P<0.01
Gp2 No change
HDL-C change
Gp1 15% elevation, P<0.01
Gp2 No change
Change in SUV
Gp1 P<0.01, Gp2 No significant change |

Abbreviations: ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CAD, coronary artery disease; CV, cardiovascular; HDL-C, high density lipoprotein cholesterol; LCBI, lipid core burden index; LDL-C, low density lipoprotein cholesterol; PAV, percent atheroma volume; PMR, plaque-to-myocardium signal-intensity ratio; RCT, randomized controlled trial; SUV, standardized uptake values; TAV, total atheroma volume.
(LDL-C) and a reduction of cardiovascular event rates has been demonstrated in numerous clinical trials (2). These studies have tested a number of lipid-lowering interventions, most notably different types of statins. Early studies used quantitative CAG to demonstrate that LDL-C lowering is associated with less progression of obstructive CAD (6). In the Familial Atherosclerosis Treatment Study (FATS), men at high risk for cardiovascular events were assessed by quantitative lipid-lowering therapy on coronary atherosclerosis (43). The mean change in the levels of LDL-C was slight in the conventional-therapy group (7%), but more substantial among patients treated with lovastatin and colestipol (46%), or niacin and colestipol (32%). In the conventional-therapy group, 46% of the patients had definite lesion progression. By comparison, progression was less frequent among patients who received lovastatin and colestipol (21%) and those who received niacin and colestipol (25%). Although a benefit on CAD progression was shown, this study evaluated men at a high risk of cardiovascular event rates and very high levels of LDL-C, with a mean LDL-C level of 189 mg/dL at baseline. Such high levels of LDL-C are not typical in most patients with CAD.

Other groups have explored the effect of lipid-modifying therapy on plaque progression in patients with mildly or moderately elevated LDL-C. In the Monitored Atherosclerosis Regression Study (MARS), the mean baseline LDL cholesterol was 151 mg/dL, and lovastatin did not produce a significant benefit on the primary endpoint of per-patient change in percent diameter stenosis measured by quantitative CAG (44). Lovastatin lowered LDL-C by 38%, and the average percent diameter stenosis increased 2.2% in the placebo group and 1.6% in the lovastatin group (P>0.20). This result, consistent with other angiographic trials of similar design, highlighted the limitations of CAG as an imaging technique to evaluate changes in atherosclerotic plaque burden, and underlined the need for studies to be conducted using vessel wall rather than lumen-based imaging modalities.

Serial coronary imaging by IVUS has shown that LDL-C lowering with high-intensity statin therapy provides benefit to atherosclerotic plaque burden (Figure 2). The REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study was a direct comparison of moderate lipid-lowering with pravastatin 40 mg and intensive lipid-lowering with atorvastatin 80 mg for 18 months (45). Baseline LDL-C (mean 3.9 or 150.2 mg/dL) levels were reduced to 2.8 mmol/L (110 mg/dL) in the pravastatin group compared with 2.0 mmol/L (79 mg/dL) in the atorvastatin arm (P<0.0001). The inflammatory biomarker C-reactive protein (CRP) decreased 5.2% with pravastatin and 36.4% with atorvastatin (P<0.0001). For all IVUS endpoints, progression occurred in the moderate-treatment cohort, and plaque volume was unchanged in the intensive arm. Direct relationships were shown between the degree of LDL-C lowering, slowing of disease progression and reduction of CRP (53). These results reflect the notion that aggressively treating CAD with statins has favorable anti-inflammatory effects in addition to lowering LDL-C levels.

The ability of very high intensity statin therapy to alter the progression of plaque burden was investigated further in the ASTEROID (A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden) trial (46). A total of 349 patients who received 40 mg/d rosuvastatin had evaluable IVUS examinations at baseline and after 24 months. Rosuvastatin therapy was associated with a mean reduction of LDL-C of approximately 33%, along with an increase of HDL-C by almost 15%. Significant plaque regression was observed with a 6.8% median reduction in total atheroma volume. As an extension of these results, rosuvastatin 40 mg/day was then directly compared to atorvastatin 80 mg/day for 24 months in the SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin) trial (47). The rosuvastatin group had lower levels of LDL-C than the atorvastatin group [62.6 vs. 70.2 mg/dL (1.62 vs. 1.82 mmol/L per liter), P<0.001], and higher levels of HDL-C [50.4 vs. 48.6 mg/dL (1.30 vs. 1.26 mmol/L per liter), P=0.01]. Despite these modest differences in final lipid profile, plaque regression was achieved to a comparable extent in both treatment groups, occurring in two thirds of the trial participants overall. Treatment with high intensity statins favorably impacted plaque progression in all subgroups of patients irrespective of baseline lipoprotein or CRP levels (54).

Further analysis of these IVUS-based statin trials has revealed that not only do these atherosclerotic plaques regress, they also become more stable (55). Statin use is pro-calcific irrespective of net plaque regression or progression, with the greatest increase of calcium found in those treated with high intensity statin therapy. Other imaging modalities have also been used to examine the effects of lipid lowering therapy on modification of atherosclerotic plaque composition. The EASY-FIT study investigated plaque stability by using OCT to serially image intermediate...
nonculprit lesions in 70 patients presenting with unstable angina and dyslipidemia, who were randomized to either 20 or 5 mg/d of atorvastatin. Imaging was performed at baseline and at 12-month follow-up (48). Lower LDL-C levels were obtained in the higher dose group (69 vs. 78 mg/dL, P=0.039), and this was associated with a significantly greater increase in fibrous cap thickness of 69% compared to 17% (P<0.001), suggesting more stable atheroma. The increase in fibrous cap thickness correlated with the decrease in serum LDL-C levels, along with decreases in high-sensitivity CRP, matrix metalloproteinase-9 and grade of OCT-measured macrophages. One single center study investigated the effects of potent statin therapy on plaque microstructures imaged by OCT (Figure 3). Fibrous cap thickness (P=0.01) was greater and the lipid arc was smaller (P=0.02) in nonculprit lipid plaques in stable patients receiving high dose statin therapy. High-dose statin therapy was associated with a greater fibrous cap thickness in patients with smaller (148.2±30.5 vs. 105.3±41.1 μm, P=0.004) but not larger lipid index (91.1±32.6 vs. 78.1±43.3 μm, P=0.21) (56). Similar results were seen in another single center study that examined the effects of the addition of ezetimibe (10 mg) to treatment with fluvastatin (30 mg) on plaque stabilization (57). The reduction in serum LDL-C was significantly larger in the ezetimibe and fluvastatin group compared with fluvastatin alone (−34.0±32.0 vs. −8.3±17.4 mg/dL, P<0.001). While fibrous cap thickness imaged by OCT significantly increased in both treatment...
groups after nine months of therapy, this change was also greater with the combination therapy (0.08±0.08 vs. 0.04±0.06 mm, P<0.001).

The PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) trial provided the first prospective natural history study of VH-IVUS-derived vulnerable plaque (58). Six hundred and ninety-seven patients with successful percutaneous coronary intervention underwent three-vessel imaging of the coronary arteries with quantitative angiography, grayscale IVUS and VH-IVUS. Thin-cap fibroatheroma (defined as fibrous cap thickness <65 μm, a minimal luminal area of 4.0 mm², and a large plaque burden of at least 70 %, were associated with higher occurrence of cardiovascular events. In the HEAVEN study, 89 patients with stable angina were treated with aggressive lipid lowering therapy of atorvastatin 80 mg and ezetimibe 10 mg or standard therapy (59). Coronary plaque burden regressed in the aggressive treatment group and progressed in the standard treatment group. However, by VH-IVUS there were no significant differences between the two arms with respect to plaque composition, with both groups showing a continuous plaque shift from fibrous and fibro-fatty to necrotic with calcification.

A subset of 71 patients from the SATURN trial underwent collection of VH-IVUS imaging along with grayscale IVUS. There were no changes in fibrous or necrotic core tissue volumes. However, a reduction in estimated fibro-fatty tissue volume accompanied atheroma regression, while dense calcium tissue volume increased, supporting the notion that statins have plaque-stabilizing effects (60).

The YELLOW (Reduction in Yellow Plaque by Intensive Lipid Lowering Therapy) trial was an open label study that compared impact of short-term intensive statin therapy on lipid content of atherosclerotic plaque (49). NIRS and IVUS were performed at baseline and after 7 weeks of treatment with either 40 mg of rosuvastatin or standard-of-care lipid-lowering therapy. Although neither group displayed a difference in plaque burden percentage measured by IVUS (standard group: from 75.6% to 74.9%; intensive group: from 75.9% to 75.3%), intensive therapy was accompanied by a greater median reduction in LCBI₄₄ mm max (lipid-core burden index at the 4 mm maximal segment) measured by NIRS [−149.1 (−210.9 to −42.9) vs. 2.4 (−36.1 to 44.7); P=0.01], meeting the study’s primary endpoint. However, it is important to note that the baseline LCBI was significantly higher in patients randomly allocated to the intensive therapy arm, and these results should be viewed as hypothesis generating rather than definitive.

Studies using non-contrast CT have also investigated
plaque stabilization by measuring the amount of coronary calcium. Pooled data from SFHS (50) and EBEAT (51) studies reported that despite the increase in CAC scores after high dose and long-term statin therapy, cardiovascular event rates did not increase, suggesting plaque repair and stabilization, not expansion (61). The well-recognized relationship between increased plaque calcification and reduced event risk, as highlighted in patients on statins, limits the ability of non-contrast CT to meaningfully evaluate CAD progression. Therefore for this type of study coronary CTA is more helpful.

Assessment of the natural history of coronary plaque by coronary CTA has generally been in the context of ACS patients or in retrospective studies. In ACS studies, such as ROMICAT (62) and a CT-substudy of PROSPECT (63), serial CT imaging at 2–3 year intervals has shown increased plaque burden due to progression of noncalcified plaque (62), along with positive remodeling (63). In another study, retrospective analysis of 60 patients who had undergone clinically indicated coronary CTA s showed that statin therapy was associated with reduction in noncalcified plaque after approximately 1 year, without affecting calcified plaque volume (64). A marked reduction of 19.4% in mean size for non-calcified plaque was also achieved following 1 year of atorvastatin therapy in a recent prospectively randomized trial of lipid lowering in HIV patients (65). Notably, the active treatment group also showed attenuation of high-risk coronary CTA features, such as low attenuation of plaque and positive remodeling.

In another statin trial, Noguchi et al. investigated the anti-atherosclerotic effect of pitavastatin using both noncontrast T1-weighted MRI and coronary CTA (9). Twelve months of therapy resulted in lowering of LDL-C from 125 to 70 mg/dL, accompanied by an 18.9% reduction in the PMR signal of coronary HIPs, and a decrease in low-attenuation plaque volume and the percentage of total atheroma volume on coronary CTA.

Early data have also indicated that FDG uptake of plaque decreases in association with statin treatment. Forty-three patients who underwent 18F-FDG-PET for cancer screening and had radio-tracer uptake in the thoracic aorta and/or carotid arteries, were either treated with simvastatin or dietary management (52). Simvastatin reduced LDL-C by 30% (P<0.01) and increased HDL-C by 15% (P<0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. Plaque inflammation visualized by 18F-FDG-PET was attenuated by simvastatin, with the decrease in SUV (standard uptake value) found to correlate with HDL-C elevation (P<0.01) but not LDL-C reduction.

A summary of the above studies is provided in Table 1. Despite a wealth of evidence to show that statin therapy and LDL-C lowering beneficially alters CAD burden and plaque composition, one in every five patients who achieve very low LDL-C levels continues to experience CAD progression (66). This phenomenon may be explained by the presence of other uncontrolled risk factors and highlights the multifactorial nature of atherosclerotic disease, and the need to also modify non-LDL-C risk factor targets.

Targeting high-density lipoprotein (HDL) (Table 2)

Several lines of evidence have strongly indicated that HDL plays a protective role in atherosclerosis. An inverse relationship between HDL-C and prospective cardiovascular risk has been demonstrated in population studies (74). This connection is demonstrated in patients with lower levels of HDL-C who continue to experience cardiovascular events despite reaching very low LDL-C levels (75). The independent link that statins possess the ability to slow plaque progression in those with modest increases in HDL-C complements similar findings from clinical event studies (76). These and other observations have led to the development of HDL-targeted anti-atherosclerotic therapies.

The promotion of HDL can be accomplished through transgenic expression of its major proteins or direct infusion, and both of these methods have been used in preclinical models. In many studies, delipidated HDL has been shown to have pleiotropic beneficial effects on atherosclerotic burden, including through promotion of rapid cholesterol efflux (77) and improvement of endothelial cell function (78).

Niacin is the most effective treatment to raise low levels of HDL-C in current clinical practice. In the pre-statin era, experience with niacin suggested benefit with immediate release formulations (79). Demonstration of anti-atherosclerotic effects of niacin was evaluated in a small Korean study that compared the effects of a combination of niacin and simvastatin to simvastatin alone, on plaque regression as measured by IVUS and inflammatory makers (80). There were no intergroup differences for normalized TAV or PAV either before or after nine months of treatment. However, the degree of change for both parameters was greater in the niacin and simvastatin combination group compared to the simvastatin
<table>
<thead>
<tr>
<th>Study and author</th>
<th>Disease cohort and study size</th>
<th>Intervention</th>
<th>Study design</th>
<th>Modality</th>
<th>Follow-up</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>ApoA-IMilano Nissen et al. (67)</td>
<td>ACS n=57</td>
<td>Gp1 ETC-216 at 15 or 45 mg/kg Gp2 Placebo</td>
<td>RCT</td>
<td>IVUS</td>
<td>5 weeks</td>
<td>Mean PAV change Gp1 −1.06%, P=0.02 Gp2 +0.14%, P=0.97</td>
</tr>
<tr>
<td>ERASE Tardif et al. (68)</td>
<td>ACS n=183</td>
<td>Gp1 CSL-111 at 40 or 80 mg/kg Gp2 Placebo</td>
<td>RCT</td>
<td>IVUS</td>
<td>4 weeks</td>
<td>Median PAV change Gp1 −3.41%, P&lt;0.01 Gp2 −1.62%, P=0.07</td>
</tr>
<tr>
<td>LS-001 Waksman et al. (69)</td>
<td>ACS n=28</td>
<td>Gp1 HDL delipidated plasma Gp2 Placebo</td>
<td>RCT</td>
<td>IVUS</td>
<td>7 weeks</td>
<td>Mean TAV change Gp1 −12.18±36.75 mm³ Gp2 +2.80±21.25 mm³, P=0.268</td>
</tr>
<tr>
<td>Chi-Square Tardif et al. (70)</td>
<td>ACS n=507</td>
<td>Gp1 CER-001 3 mg/kg Gp2 CER-001 6 mg/kg Gp3 CER-001 12 mg/kg Gp4 Placebo</td>
<td>RCT</td>
<td>IVUS</td>
<td>9 weeks</td>
<td>Nominal TAV change Gp1 −3.13 mm³ vs. placebo, P=0.77 Gp2 −1.50 mm³ vs. placebo, P=0.45 Gp3 −3.05 mm³ vs. placebo, P=0.81 Gp4 −2.71 mm³</td>
</tr>
<tr>
<td>ILLUSTRATE Nissen et al. (71)</td>
<td>Stable CAD n=1,188</td>
<td>Gp1 torcetrapib 60 mg Gp2 Placebo</td>
<td>RCT</td>
<td>IVUS</td>
<td>24 months</td>
<td>Mean HDL-C change Gp1 58.6% Gp2 −2.2%, P&lt;0.001 Mean PAV change Gp1 0.12±2.99 Gp2 0.19±2.83, P=0.72</td>
</tr>
<tr>
<td>RADIANCE 1 Kastelein et al. (72)</td>
<td>Heterozygous familial hypercholesterolemia n=850</td>
<td>Gp1 torcetrapib 60 mg Gp2 Placebo</td>
<td>RCT</td>
<td>CIMT</td>
<td>24 months</td>
<td>Mean HDL-C change Gp1 54.4% Gp2 2.5%, P&lt;0.001 Change max over 12 segments Gp1 0.0047 Gp2 0.0053, P=0.87</td>
</tr>
<tr>
<td>RADIANCE 2 Bots et al. (73)</td>
<td>Mixed dyslipidemia n=752</td>
<td>Gp1 torcetrapib 60 mg Gp2 Placebo</td>
<td>RCT</td>
<td>CIMT</td>
<td>24 months</td>
<td>Mean HDL-C change Gp1 61.6% Gp2 −1.8%, P&lt;0.001 Yearly change max over 12 segments Gp1 0.025 mm Gp2 0.030 mm, P=0.46</td>
</tr>
</tbody>
</table>

Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; CIMT, carotid intima-media thickness; Gp., group; HDL-C, high density lipoprotein-cholesterol; IVUS, intravascular ultrasound; LDL-C, low density lipoprotein-cholesterol; Max, maximum; PAV, percent atheroma volume; RCT, randomized controlled trial; TAV, total atheroma volume.
monotherapy group ($\Delta$TAV: $-21.6\pm10.7$ vs. $5.3\pm42.2$, $P=0.024$; $\Delta$PAV: $-1.2\pm2.5$ vs. $-0.6\pm5$, $P=0.047$). This occurred in parallel with greater changes in hs-CRP, MMP-9, and sCD40L in the combination group. Surprisingly, data for the effect of niacin on HDL and LDL were not provided. While these results are positive, the use of niacin is limited because of patient intolerance and an ongoing perception that it does not confer additional benefit to statin therapy (81). In particular, a recent study failed to show an additive benefit of extended-release niacin either as monotherapy, or in combination with a prostanoid receptor antagonist to reduce flushing, on cardiovascular events in statin-treated patients (82). Niacin is also associated with other adverse effects, including septic and hemorrhagic complications (83). It must be emphasized that the failure of niacin to demonstrate a clinical benefit should not be interpreted as a failure of the HDL hypothesis, as it has multiple additional mechanisms of action.

The potential benefit of infusing lipid-deplete forms of HDL into humans has been demonstrated in four clinical trials. In the first of these, ACS patients were treated with intravenous infusions of reconstituted HDL containing apoA-I Milano (AIM) or placebo (saline) for 5 weeks (67). IVUS imaging was conducted at baseline and at the end of treatment, and rapid regression of atherosclerosis was observed in those who received the AIM infusions. Notably, these benefits were observed without any change in lumen size, suggesting that they would not have been detected by CAG alone. This finding also supports the notion that plaque regression is accompanied by reverse remodeling of the artery wall (84). In the second study, ERASE (The Effect of rHDL on Atherosclerosis Safety and Efficacy), patients received 4 weekly infusions of HDL particles containing wild-type apoA-I or a placebo of saline (68). After the short period of infusions, there was no significant difference detected by IVUS for coronary atheroma volume between active and placebo groups.

In the Lipid Sciences Selective Delipidation Trial (LS-001), 28 ACS patients underwent plasma apheresis and were randomized to 7 weekly autologous reinusions of selective HDL delipidated plasma or control plasma (69). IVUS was performed at baseline and up to fourteen days after the last infusion. Reinusions were well tolerated. There was a numerical, non-significant trend toward regression in the total atheroma volume in the delipidated group compared to a small increase in the control group. In the latest HDL infusion study, Chi-Square (Can HDL Infusions Significantly Quicken Atherosclerosis Regression?), patients were allocated to receive 6 weekly infusions of either saline, or three different doses of CER-001 (Cerenis Therapeutics, Labège, France), a novel engineered HDL-mimetic comprised of recombinant human apoA-I and phospholipids, and designed to mimic the benefits of nascent pre-β HDL. Although there was no statistically significant difference between the active treatment groups and placebo, CER-001 was associated with an inverse, dose-dependent response for the change in coronary atheroma volume (70). This has prompted ongoing evaluation in the recently launched Phase II CARAT study in patients with ACS (www.clinicaltrials.gov NCT02484378). Pending further large-scale evaluation, each of the above-mentioned studies supports the feasibility and safety of treating human patients with HDL infusions, while hinting at their anti-atherosclerotic benefits.

The HDL field has also seen the development of cholesteryl ester transfer protein (CETP) inhibitors, which can substantially raise HDL-C levels. CETP promotes the transfer of cholesteryl esters from HDL to lipoproteins, including LDL and VLDL particles (85). Therefore inhibiting CETP leads to increased HDL-C levels and can prevent cholesterol enrichment of atherogenic lipoproteins. CETP exists in the plasma of a few species, including humans and rabbits, but not rodents. Transgenic mice have been engineered to express CETP, resulting in the development of atherosclerosis (86,87). Different murine models have provided discordant results, with some indicating that CETP is antiatherogenic (88-90), and others that it is proatherogenic (91-93). Rabbits are highly susceptible to the development of diet-induced atherosclerosis, and have a naturally high level of CETP. In one study, CETP was inhibited in rabbits by infusing anti-CETP antibodies, which led to a rise in HDL cholesterol ester, and a fall in triglyceride levels (94). Despite this, levels of HDL protein did not change, suggesting a cholesterol ester for triglyceride exchange. Another study used a chemical inhibitor of CETP in cholesteryl-fed rabbits, which reduced CETP activity by >90% and almost doubled serum HDL-C, while decreasing non-HDL-C by approximately 50% (95). These lipid changes were accompanied by a 70% reduction in aortic atherosclerotic burden, supporting the anti-atherogenic potential for CETP inhibitors.

Human data also provided impetus for the clinical evaluation of CETP inhibitors, including the observation that populations with a high prevalence of low CETP activity have fewer cardiovascular events, when
accompanied by high HDL-C levels (96). The effect of the CETP inhibitor, torcetrapib, on atherosclerosis was evaluated in number of imaging trials. The ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) study used IVUS to assess the effect of torcetrapib on the progression of atheroma burden in patients treated with atorvastatin for a LDL-C goal of 100 mg/dL (71). B-mode ultrasound was also used to assess the effects of torcetrapib on carotid intima-media thickness (CIMT) in patients with familial hypercholesterolemia in the RADIANCE 1 (The Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor) study (72), and mixed hyperlipidemia in the RADIANCE 2 (The Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor) study (73). The Torcetrapib-treated patients showed an increase in HDL-C concentration by approximately 60% in all three of these imaging trials. LDL-C levels were also reduced by approximately 20% more than that achieved by atorvastatin alone. Despite these results, treatment with torcetrapib had no effect on slowing disease progression or promoting regression of the coronary arteries (71) or on CIMT (72,73).

The first large-scale clinical trial with torcetrapib, conducted in parallel with these imaging studies, was prematurely terminated due to high rates of cardiovascular events and mortality (97). A post-hoc analysis of ILLUSTRATE demonstrated an inverse relationship between the extent of HDL-C increases in those treated with torcetrapib and the rate of atherosclerotic progression, with plaque regression observed in patients who achieved the highest levels of HDL-C (98). These and other results suggest an intact capacity of HDL to reduce the size of atheroma burden and to promote cholesterol efflux after torcetrapib treatment and in CETP-deficient individuals (98,99). The adverse effects seen with torcetrapib may reflect a molecule-specific problem, while the drug has also been shown to have a number of off-target toxic effects at the level of the artery wall and adrenal gland (100). Despite the cautionary tale of torcetrapib, there are ongoing efforts to develop and refine other CETP inhibitors that do not contain these toxicities.

Generating nascent functional HDL particles is another strategy to target HDL. Upregulating endogenous synthesis of apoA-I should create nascent HDL particles that would travel in the systemic circulation, and carry out physiological activities, such as cholesterol efflux and anti-inflammatory functions. This process should theoretically avoid the potential impact of modifying complex remodelling pathways involved in lipid metabolism. Preclinical studies conducted by treating nonhuman primates with RVX-208 showed an increase in hepatic apoA-I synthesis, and enhanced cholesterol efflux capacity (101). Early studies that treated CAD patients with statins and RVX-208 or placebo for 12 weeks showed an increase in apoA-I, HDL-C, and concentration of large HDL particles in those receiving RVX-208. Although these encouraging results indicated facilitation of cholesterol mobilization (102), they were not associated with a positive impact on coronary plaque burden, and the clinical benefit of this therapeutic strategy remains undetermined (103).

Taken together, there have been numerous efforts to modify HDL levels and function with variable success at altering the atherosclerotic substrate (Table 2). The completed studies in the field have had important limitations and their results have been far from definitive. Nevertheless, there remains enthusiasm for the development of effective HDL-modifying therapies and the application of atherosclerotic imaging techniques will be integral to their evaluation.

Targeting diabetes (Table 3)

The increased prevalence of type 2 diabetes is a major factor contributing to the prediction that cardiovascular disease will become the leading cause of mortality worldwide by 2020 (108). In addition to having a substantially increased risk of adverse cardiovascular events (109), diabetic patients also suffer from less favorable outcomes post-MI (110) and following coronary interventions (111). The association between CAC and future cardiovascular events has been observed in patients with diabetes (112). The diabetes heart study (DHS) showed an increase in mortality with increasing levels of CAC in 1,051 diabetic patients (113). There is also an association of greater plaque burden and disease progression in the arterial wall of diabetic patients, including a higher prevalence of impaired compensatory remodeling which is associated with adverse plaque events (114). While aggressively lowering LDL-C levels is associated with a favorable impact on plaque progression, diabetic patients have traditionally demonstrated greater increases in atheroma volume (114). However, in a recent analysis of the SATURN trial, the diabetic patients demonstrated regression of atherosclerotic plaque. Disease regression was greater in the nondiabetic patients when LDL-C levels were $>70$ mg/dL [($0.31\pm0.23$)% vs. ($1.01\pm0.21$)%; $P=0.03$] but...
similar when LDL-C levels were $\leq 70$ mg/dL [(-1.09±0.16)\% vs. (-1.24±0.16)\%, P=0.50] (115). This reaffirms the antiatherogenic benefits of tight lipid control in the setting of diabetes.

Peroxisome proliferation-activated receptor gamma (PPARγ) agonists are widely used as insulin sensitisers in diabetes. PPARγ activation encompasses several biological functions in different cell types and tissues, such as regulating metabolism, reducing inflammation, improving endothelial function, and inhibiting apoptosis and oxidative stress. These functions not only have a positive effect on diabetes, but on atherosclerosis as well. A number of trials have investigated this for the PPARγ agonist, pioglitazone, which can also raise HDL-C levels. The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study, and the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study both directly compared the impact of pioglitazone and the sulfonylurea agent, glimepiride, in patients with diabetes (Table 3). The halting of CIMT (104) and coronary atheroma progression, as assessed by IVUS (105), was associated with lower levels of triglycerides and CRP, and higher levels of HDL-C, along with improvement in glycemic control in the pioglitazone group. Further analyses of both studies revealed that raising HDL-C was the strongest independent predictor of the ability of pioglitazone to slow plaque progression (116,117). The incremental benefit shown by targeting multiple metabolic risk factors supports the need to aggressively treat all cardiovascular risk factors in patients with diabetes (118).

**Blood pressure (BP) lowering (Table 3)**

Hypertension is a major contributing risk factor to the worldwide escalation of cardiovascular disease, with well-established evidence to support the clinical benefit of different BP-lowering therapies in hypertensive patients (119). Although a few studies have also reported that progression of CIMT is highly sensitive to BP reduction (120), the effect of anti-hypertensive treatments on CAD progression has not been investigated in great detail.

The CAMELOT (Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis) study evaluated the effect of amlodipine, enalapril and placebo on clinical event rates in patients with established CAD and BP that was considered to be optimally controlled (diastolic BP <100 mmHg) (106). Its IVUS sub-study revealed that amlodipine treatment slowed atherosclerotic disease progression, as well as lowering cardiovascular event rates (121). There was also a direct relationship between the achieved levels of systolic BP and disease progression, with a trend towards atheroma regression in patients who achieved a systolic BP <120 mmHg.

Preclinical data have demonstrated that activation of the renin-angiotensin-aldosterone system (RAAS) plays a particularly important role in atherogenesis (122) and that RAAS inhibition may therefore have favourable effects on the artery wall (123). However, in the AQUARIUS (Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study) study, the direct renin inhibitor, aliskerin, failed to have any effect on IVUS-measured plaque progression when compared to placebo, in patients with prehypertensive BP (107). Although as yet under investigated, there is scope for future imaging studies to compare the anti-atherosclerotic properties of different anti-hypertensive agents, including angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, in patients with stable and unstable CAD.

**Novel therapies and future directions**

Serial imaging of the vessel wall has provided the opportunity to explore the effects of novel therapies on atherosclerotic plaque. As effective as statins are for lowering levels of LDL-C, there is still an unmet need for additional or alternative LDL-C-lowering therapies. This is especially so in patients with statin intolerance and those with severe hypercholesterolemia (e.g., familial syndromes) who fail to achieve target cholesterol levels with conventional agents and doses. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a promising new class of drugs for LDL-C reduction that are approved for use and are currently being evaluated in clinical trials including the IVUS-based GLAGOV study (http://clinicaltrials.gov NCT01663402). Another therapeutic target that has yet to be fully explored is triglyceride- rich lipoprotein particles that have potent atherogenic effects (124). Elevated triglyceride levels predict patients at increased vascular risk (125). To date, there is a paucity of information on the ability of triglyceride-lowering drugs (e.g., fibrates) to modulate the natural history of coronary atheroma in human patients.

The effects of lifestyle interventions such as smoking...
and weight loss have yet to be investigated fully. However, a study done by Madssen et al. investigated effects of aerobic interval training (AIT) versus moderate continuous training (MCT) on coronary atherosclerosis in patients with significant CAD on optimal medical treatment (126). Patients were randomized to AIT or MCT for 12 weeks after intracoronary stent implantation. Grayscale and VH-IVUS were performed at baseline and follow-up. Necrotic core was reduced in both groups in defined coronary segments (AIT −3.2%, MCT −2.7%, P<0.05) and in separate lesions (median change −2.3% and −0.15 mm³, P<0.05). Plaque burden was also reduced by 10.7% in separate lesions independent of intervention group (P=0.06). Although there was a lack of difference in plaque regression between the two modes of exercise training, the overall favorable effects of exercise should encourage further evaluation.

Other treatments with potential anti-atherogenic benefits, including anti-inflammatory drugs, omega-3 fatty acids, and various experimental agents (e.g., small molecules, gene and cell-based therapies) may also be future candidates for serial studies.

<table>
<thead>
<tr>
<th>Study and author</th>
<th>Disease cohort and study size</th>
<th>Intervention</th>
<th>Study design</th>
<th>Modality</th>
<th>Follow-up</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHICAGO, Mazzone et al. (104)</td>
<td>Type 2 diabetes mellitus n=462</td>
<td>Gp1 glimepiride 1 to 4 mg/day Gp2 pioglitazone 15 to 45 mg/day</td>
<td>RCT</td>
<td>CIMT</td>
<td>18 months</td>
<td>Mean change in posterior wall CIMT Gp1 +0.012 mm, Gp2 −0.001 mm, P=0.2</td>
</tr>
<tr>
<td>PERISCOPE, Nissen et al. (105)</td>
<td>Type 2 diabetes mellitus n=543</td>
<td>Gp1 glimepiride 1 to 4 mg/day Gp2 pioglitazone 15 to 45 mg/day</td>
<td>RCT</td>
<td>IVUS</td>
<td>18 months</td>
<td>Mean PAV change Gp1 +0.73%, Gp2 −0.16%, P=0.002</td>
</tr>
<tr>
<td>CAMELOT IVUS Substudy, Nissen et al. (106)</td>
<td>Hypertensive CAD n=274</td>
<td>Gp1 amlodipine 10 mg Gp2 enalapril 20 mg Gp3 placebo</td>
<td>RCT</td>
<td>IVUS</td>
<td>24 months</td>
<td>Mean BP change Gp1 −4.8/2.5 mmHg Gp2 −4.9/2.4 mmHg Gp3 +0.7/0.6 mmHg P&lt;0.001 Group 1 and 2 vs. Group 3 Mean PAV change Gp1 +0.5%, P=0.31 Gp2 +0.8%, P=0.08 Gp3 +1.3%, P=0.001</td>
</tr>
<tr>
<td>AQUARIUS, Nicholls et al. (107)</td>
<td>Prehypertensive CAD n=613</td>
<td>Gp1 aliskiren 300 mg Gp2 placebo</td>
<td>RCT</td>
<td>IVUS</td>
<td>18 months</td>
<td>Final systolic BP Gp1 128.3 (127.2 to 129.4) mmHg Gp2 130.4 (129.3 to 131.5) mmHg, P=0.007 Final diastolic BP Gp1 75.3 (74.6 to 76) mmHg Gp2 76.8 (76.1 to 77.5) mmHg, P=0.003 Mean PAV change Gp1 −0.33%, Gp2 +0.11%, P=0.08</td>
</tr>
</tbody>
</table>

Abbreviations: BP, blood pressure; CAD, coronary artery disease; CIMT, carotid intima-media thickness; PAV, percent atheroma volume; RCT, randomized controlled trial.
coronary imaging studies. The ability to determine whether such agents have a beneficial effect on plaque progression can provide important support to either advance or halt clinical development of new therapies. Examples of the latter include the discontinuation of active research programs investigating the use of compounds such as endocannabinoid receptor antagonists (127) and acyl-coenzyme A cholesterol acyltransferase inhibitors (128), after negative results.

Summary

The technological advances that have been made with vessel wall imaging modalities have greatly increased the ability to evaluate the full extent of atherosclerotic plaque within the coronary vasculature. Some of the anti-atherosclerotic therapeutic strategies currently available have demonstrated slowing of disease progression and even plaque regression. However, there continues to be a need to develop novel therapies to aggressively target high-risk atherosclerotic lesions, and the evolution and increasing use of coronary imaging techniques will play a central role in determining their effectiveness.

Acknowledgements

Funding: Dr. Psaltis receives funding from the National Health and Medical Research Council (PG1086796) and Heart Foundation (FLF100412) of Australia. Dr. Puri is currently supported by a Neil Hamilton Fairley Early Career Fellowship grant from the National Health and Medical Research Council.

Footnote

Conflicts of Interest: Dr. Nicholls; Research Grant; Modest; Anthera, AstraZeneca, Cerenis, Eli Lilly, InfraReDx, Roche, Resverlogix, Novartis, Amgen, and LipoScience. Speakers Bureau; Modest; AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda. Consultant/Advisory Board; Modest; AstraZeneca, Abbott, AtheroNova, Esperion, Amgen, Novartis, Onthera, CSL Behring, Boehringer Ingelheim, Pfizer, Merck Schering-Plough, Takeda, Roche, Novo Nordisk, LipoScience, and Anthera. None of the other authors has relevant disclosures.

References


99. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257-60.

100. Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 2009;104:32E-8E.


